Grand Hopital De Charleroi
- Address
- Rue De Villers 1, 6280 Gerpinnes, Belgium
Disorders of Environmental Origin
At Grand Hopital De Charleroi researchers are investigating supportive treatments for patients with severe thermal injuries, aiming to reduce organ failure and improve survival.
- Evaluating adjunctive antioxidant therapy in burn care
- Monitoring composite outcomes of organ dysfunction and mortality
- Assessing safety of high‑dose intravenous interventions
The trials focus on translating experimental findings into practical strategies for critically injured patients.
Immune System Diseases
Clinical programs at the site target chronic inflammatory skin conditions such as hidradenitis suppurativa and severe eczema, testing novel agents and optimized dosing approaches.
- Upadacitinib efficacy in patients unresponsive to TNF inhibitors
- Tralokinumab impact on moderate‑to‑severe hand eczema
- Proactive therapeutic drug monitoring for biologic-treated psoriasis
These studies seek to expand therapeutic options and personalize management for immune‑mediated dermatologic diseases.
Neoplasms
The oncology team is conducting early‑phase research on recurrent ovarian and MUC16‑positive cancers, exploring innovative immunotherapy combinations.
- Determining safety and dosing of ubamatamab alone or with cemiplimab
- Measuring objective response rates using RECIST criteria
- Identifying maximum tolerated and recommended phase‑2 doses
The goal is to establish effective treatment regimens for patients with limited options after standard therapy.
Skin and Connective Tissue Diseases
Investigations at the centre address a spectrum of dermatologic disorders, including moderate‑to‑severe psoriasis and atopic skin disease, to improve disease control and patient quality of life.
- Comparing proactive TDM versus standard biologic use in psoriasis
- Assessing long‑term disease control across multiple biologic agents
- Evaluating systemic therapies for atopic dermatitis and hand eczema
These efforts aim to refine therapeutic strategies and deliver sustained relief for chronic skin conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Grand Hopital De Charleroi
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND) | Leo Pharma A/S | Phase I | Not Recruiting | May 2024 | Sep 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ascorbic Acid | 1 | Unknown | 2022-11-22 | 2022-11-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.